Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-08-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2012-01-405977PMID 22529291PMCID PMC3412329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gene Expression Omnibus (GEO)

  2013cited by this paper
• Clonal competition with alternating dominance in multiple myeloma.

  2012cited by this paper
• The leukemogenic AF4–MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures

  2011cited by this paper
• Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Integrative Genomics Viewer

  2011cited by this paper
• [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].

  2011cited by this paper
• Faculty Opinions recommendation of Initial genome sequencing and analysis of multiple myeloma.

  2011cited by this paper
• A method and server for predicting damaging missense mutations

  2010cited by this paper
• A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.

  2010cited by this paper
• MutationTaster evaluates disease-causing potential of sequence alterations

  2010cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

  2009cited by this paper
• Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis

  2009cited by this paper
• Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics

  2009cited by this paper
• Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

  2009cited by this paper
• New insights to the MLL recombinome of acute leukemias

  2009cited by this paper
• Genetic aberrations and survival in plasma cell leukemia

  2008cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.

  2007cited by this paper
• The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling.

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007influential reference
• Analysis of PTEN deletions and mutations in multiple myeloma.

  2006cited by this paper
• Molecular pathogenesis and a consequent classification of multiple myeloma.

  2005cited by this paper
• Clinical and biologic implications of recurrent genomic aberrations in myeloma.

  2003cited by this paper
• Multiple myeloma: evolving genetic events and host interactions

  2002cited by this paper
• Hypodiploidy is a major prognostic factor in multiple myeloma.

  2001cited by this paper
• Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

  2001cited by this paper
• Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

  1998cited by this paper
• The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

  1998cited by this paper
• Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

  1997cited by this paper
• Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.

  1996influential reference
• A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells.

  1995cited by this paper
• High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells

  1995cited by this paper
• Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.

  1994cited by this paper
• Deletion of the retinoblastoma gene in multiple myeloma.

  1994cited by this paper
• Plasma cell leukemia: an evaluation of response to therapy.

  1987cited by this paper

• The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

  2026cites this paper
• Research Progress on the Functional Regulation Mechanisms of ZKSCAN3

  2025cites this paper
• Long-Term Survival with Multiple Myeloma: An Italian Experience

  2025cites this paper
• Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma.

  2025cites this paper
• Strategies for the drug development of cancer therapeutics

  2025cites this paper
• Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment

  2025cites this paper
• MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study

  2025cites this paper
• Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases

  2025cites this paper
• Is Consolidation Therapy Effective in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Single Center Real-Life Data with Cyclophosphamide-Bortezomib-Dexamethasone or Bortezomib-Lenalidomide-Dexamethasone?

  2025cites this paper
• Heterogeneidad molecular en mieloma múltiple

  2024cites this paper
• The Biological Roles of ZKSCAN3 (ZNF306) in the Hallmarks of Cancer: From Mechanisms to Therapeutics

  2024influential citation
• The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward

  2024cites this paper
• The significance of RB1 in multiple myeloma

  2024cites this paper
• NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway

  2024cites this paper
• Single-cell genomics-based immune and disease monitoring in blood malignancies

  2024cites this paper
• CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy

  2024cites this paper
• Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation

  2024cites this paper
• Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

  2024cites this paper
• Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma

  2024cites this paper
• A systematic literature review on clonal evolution events preceding relapse in multiple myeloma.

  2024cites this paper
• Medical Image Analysis of Multiple Myeloma Diagnosis Using CNN and KNN Based Approach

  2023cites this paper
• Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma

  2023cites this paper
• Molecular and immunological mechanisms of clonal evolution in multiple myeloma

  2023cites this paper
• Identification of long noncoding RNA NEAT1 as a key gene involved in the extramedullary disease of multiple myeloma by bioinformatics analysis

  2023cites this paper
• 伴有染色体碎裂化异常的多发性骨髓瘤3例

  2022cites this paper
• The Hereditary and Epigenetic Fusion Gene Signatures of Multiple Myeloma

  2022cites this paper
• The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance

  2022cites this paper
• Development of Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome after Conversion from Plasmacytoma of Bone to Multiple Myeloma

  2022cites this paper
• I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

  2022cites this paper
• Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

  2022cites this paper
• Incidence, Time Trends and Geographical Distribution of Leukemia and Multiple Myeloma in Golestan Province, Northern Iran, 2004–2017

  2022cites this paper
• Accurate Identification of Subclones in Tumor Genomes

  2022cites this paper
• CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status

  2022cites this paper
• Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms.

  2022cites this paper
• Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine

  2022cites this paper
• In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations

  2022cites this paper
• Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma

  2022cites this paper
• The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells

  2022cites this paper
• Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias

  2022cites this paper
• The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease

  2022cites this paper
• The role of pomalidomide in treatment of relapse and refractory multiple myeloma

  2022cites this paper
• Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma

  2021cites this paper
• BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

  2021cites this paper
• Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications

  2021cites this paper
• Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

  2021cites this paper
• Mutation-dependent treatment approaches for patients with complex multiple myeloma

  2021cites this paper
• A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

  2021cites this paper
• Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma

  2021cites this paper
• Co-evolution of tumor and immune cells during progression of multiple myeloma

  2021cites this paper
• Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia

  2021cites this paper
• Smoldering multiple myeloma - Past, present, and future.

  2021cites this paper
• Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications

  2021cites this paper
• Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition

  2021cites this paper
• The Immunity‐malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells

  2021cites this paper
• DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

  2021cites this paper
• The Cancer Genome: Paradigm or Paradox?

  2021cites this paper
• Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma

  2021cites this paper
• Role of cell-free DNA in haematological malignancies.

  2021cites this paper
• Identi cation of key genes in relapsed multiple myeloma by weighted gene co-expression network analysis

  2021cites this paper
• Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches.

  2021cites this paper
• Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

  2021cites this paper
• Genome Instability in Multiple Myeloma: Facts and Factors

  2021cites this paper
• Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH

  2021cites this paper
• Plasma Cell Neoplasms

  2021cites this paper
• Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.

  2021cites this paper
• DMG26: A Targeted Sequencing Panel for Mutation Profiling to Address Gaps in the Prognostication of Multiple Myeloma.

  2021cites this paper
• Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma

  2021cites this paper
• Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition

  2021cites this paper
• Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment

  2021cites this paper
• A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics

  2021cites this paper
• Clinical case history Alternating dominance of competing myeloma clones

  2020cites this paper
• Early relapse after complete remission of primary plasma cell leukaemia manifesting clonal evolution: A case report.

  2020cites this paper
• The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

  2020cites this paper
• Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches

  2020cites this paper
• The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma

  2020cites this paper
• Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.

  2020cites this paper
• Somatic Genomic Mosaicism in Multiple Myeloma

  2020cites this paper
• Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.

  2020cites this paper
• Liquid biopsies for multiple myeloma in a time of precision medicine

  2020cites this paper
• Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma

  2020cites this paper
• Molecular basis of clonal evolution in multiple myeloma

  2020cites this paper
• Bortezomib Treatment Modulates Autophagy in Multiple Myeloma

  2020cites this paper
• The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?

  2020cites this paper
• BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

  2020cites this paper
• Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

  2020cites this paper
• Efficacy of Panobinostat for the Treatment of Multiple Myeloma

  2020cites this paper
• Developments in consolidation and maintenance strategies in post-remission multiple myeloma

  2020cites this paper
• Monoclonal gammopathies of undetermined significance and smoldering myeloma

  2020cites this paper
• Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

  2020cites this paper
• Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)

  2020cites this paper
• Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?

  2020cites this paper
• Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma.

  2020cites this paper
• The clonal evolution during long-term clinical course of multiple myeloma

  2020cites this paper
• The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability

  2020cites this paper
• An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics

  2020cites this paper
• The utility of non‐invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma

  2020cites this paper
• Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients

  2019cites this paper
• Clonal evolution in myeloma: a narrow road to remission

  2019cites this paper
• Biology and therapy of multiple myeloma

  2019cites this paper
• Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma

  2019cites this paper